Neurological manifestations of autosomal dominant familial Alzheimer's disease: a comparison of the published literature with the Dominantly Inherited Alzheimer Network observation...
- Autores
- Tang, Mengxuan; Ryman, Davis C.; McDade, Eric; Jasielec, Mateusz S.; Buckles, Virginia D.; Cairns, Nigel J.; Fagan, Anne M.; Goate, Alison; Marcus, Daniel S.; Xiong, Chengjie; Allegri, Ricardo Francisco; Chhatwal, Jasmeer P.; Danek, Adrian; Farlow, Martin R.; Fox, Nick C.; Ghetti, Bernardino; Graff-Radford, Neill R.; Laske, Christopher; Martins, Ralph N.; Masters, Colin L.; Mayeux, Richard P.; Ringman, John M.; Rossor, Martin N.; Salloway, Stephen P.; Schofield, Peter R.; Morris, John C.; Bateman, Randall J.
- Año de publicación
- 2016
- Idioma
- inglés
- Tipo de recurso
- artículo
- Estado
- versión publicada
- Descripción
- Background Autosomal dominant familial Alzheimer's disease (ADAD) is a rare disorder with non-amnestic neurological symptoms in some clinical presentations. We aimed to compile and compare data from symptomatic participants in the Dominantly Inherited Alzheimer Network observational study (DIAN-OBS) with those reported in the literature to estimate the prevalences of non-amnestic neurological symptoms in participants with ADAD. Methods We prospectively collected data from the DIAN-OBS database, which recruited participants from study centres in the USA, Europe, and Australia, between Feb 29, 2008, and July 1, 2014. We also did a systematic review of publications to extract individual-level clinical data for symptomatic participants with ADAD. We used data for age of onset (from first report of cognitive decline), disease course from onset to death, and the presence of 13 neurological findings that have been reported in association with ADAD. Using multivariable linear regression, we investigated the prevalences of various non-amnestic neurological symptoms and the contributions of age of onset and specific mutation type on symptoms. Findings The DIAN-OBS dataset included 107 individuals with detailed clinical data (forming the DIAN-OBS cohort). Our systematic review yielded 188 publications reporting on 1228 symptomatic individuals, with detailed neurological examination descriptions available for 753 individuals (forming the published data cohort). The most prevalent non-amnestic cognitive manifestations in participants in the DIAN-OBS cohort were those typical of mild to moderate Alzheimer's disease, including visual agnosia (55·1%, 95% CI 45·7–64·6), aphasia (57·9%, 48·6–67·3), and behavioural changes (61·7%, 51·5–70·0). Non-amnestic cognitive manifestations were less prevalent in the published data cohort (eg, visual agnosia [5·6%, 3·9–7·2], aphasia [23·0%, 20·0–26·0], and behavioural changes [31·7%, 28·4–35·1]). Prevalence of non-cognitive neurological manifestations in the DIAN-OBS cohort was low, including myoclonus and spasticity (9·3%, 95% CI 3·8–15·0), and seizures (2·8%, 0·5–5·9) and moderate for parkinsonism (11·2%, 5·3–17·1). By constrast, prevalence was higher in the published data cohort for myoclonus and spasticity (19·4%, 16·6–22·2 and 15·0%, 12·5–17·6, respectively), parkinsonism (12·5%, 10·1–15·0), and seizures (20·3%, 17·4–23·2). In an analysis of the published data cohort, ischaemic stroke was more prevalent at older ages of onset of symptoms of ADAD (odds ratio 1·09 per 1 year increase in age of onset, 95% CI 1·04–1·14, p=0·0003); and motor symptoms were more common at younger age of onset (myoclonus 0·93, 0·90–0·97, p=0·0007; seizures 0·95, 0·92–0·98, p=0·0018; corticobulbar deficits 0·91, 0·86–0·96, p=0·0012; and cerebellar ataxia 0·82, 0·74–0·91, p=0·0002). In the DIAN-OBS cohort, non-cognitive symptoms were more common at more severe stages of disease. Interpretation The non-cognitive clinical manifestations of Alzheimer's disease seem to affect a small proportion of participants with mild to moderate ADAD, and are probably influenced by disease severity, environmental, and genetic factors. When evaluating patients with potential ADAD, clinicians should note that cognitive symptoms typical of sporadic Alzheimer's disease are the most consistent finding, with some patients manifesting non-cognitive neurological symptoms. Future work is needed to determine the environmental and genetic factors that cause these neurological symptoms. Funding National Institutes of Health and German Center for Neurodegenerative Diseases.
Fil: Tang, Mengxuan. Washington University. School of Medicine; Estados Unidos
Fil: Ryman, Davis C.. Washington University. School of Medicine; Estados Unidos
Fil: McDade, Eric. Washington University. School of Medicine; Estados Unidos
Fil: Jasielec, Mateusz S.. Washington University. School of Medicine; Estados Unidos
Fil: Buckles, Virginia D.. Washington University. School of Medicine; Estados Unidos
Fil: Cairns, Nigel J.. Washington University. School of Medicine; Estados Unidos
Fil: Fagan, Anne M.. Washington University. School of Medicine; Estados Unidos
Fil: Goate, Alison. Washington University. School of Medicine; Estados Unidos
Fil: Marcus, Daniel S.. Washington University. School of Medicine; Estados Unidos
Fil: Xiong, Chengjie. Washington University. School of Medicine; Estados Unidos
Fil: Allegri, Ricardo Francisco. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Chhatwal, Jasmeer P.. Brigham and Women’s Hospital; Estados Unidos
Fil: Danek, Adrian. Ludwig-Maximilians Universität Munich. Neurologische Klinik; Alemania
Fil: Farlow, Martin R.. Indiana University; Estados Unidos
Fil: Fox, Nick C.. University College London; Estados Unidos
Fil: Ghetti, Bernardino. Indiana University; Estados Unidos
Fil: Graff-Radford, Neill R.. Mayo Clinic; Estados Unidos
Fil: Laske, Christopher. German Center for Neurodegenerative Diseases and Hertie Institute for Clinical Brain Research; Alemania
Fil: Martins, Ralph N.. Edith Cowan University. School of Exercise, Biomedical and Health Sciences. Centre of Excellence for Alzheimer’s Disease Research and Care; Australia
Fil: Masters, Colin L.. University of Melbourne. Mental Health Research Institute; Australia
Fil: Mayeux, Richard P.. Columbia University Medical Center. Taub Institute for Research on Alzheimer’s Disease and the Aging Brain; Estados Unidos
Fil: Ringman, John M.. University of Southern California. Keck School of Medicine; Estados Unidos
Fil: Rossor, Martin N.. University College London; Estados Unidos
Fil: Salloway, Stephen P.. Brown University. Warren Alpert Medical School; Estados Unidos
Fil: Schofield, Peter R.. University of New South Wales; Australia
Fil: Morris, John C.. University of Washington; Estados Unidos
Fil: Bateman, Randall J.. University of Washington; Estados Unidos - Materia
-
Dominantly Inherited Alzheimer
Neurological
Symptoms
Familial Alzheimer - Nivel de accesibilidad
- acceso abierto
- Condiciones de uso
- https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
- Repositorio
- Institución
- Consejo Nacional de Investigaciones Científicas y Técnicas
- OAI Identificador
- oai:ri.conicet.gov.ar:11336/51545
Ver los metadatos del registro completo
id |
CONICETDig_578d4b4ba14bd2538ef55f1dbf660149 |
---|---|
oai_identifier_str |
oai:ri.conicet.gov.ar:11336/51545 |
network_acronym_str |
CONICETDig |
repository_id_str |
3498 |
network_name_str |
CONICET Digital (CONICET) |
spelling |
Neurological manifestations of autosomal dominant familial Alzheimer's disease: a comparison of the published literature with the Dominantly Inherited Alzheimer Network observational study (DIAN-OBS)Tang, MengxuanRyman, Davis C.McDade, EricJasielec, Mateusz S.Buckles, Virginia D.Cairns, Nigel J.Fagan, Anne M.Goate, AlisonMarcus, Daniel S.Xiong, ChengjieAllegri, Ricardo FranciscoChhatwal, Jasmeer P.Danek, AdrianFarlow, Martin R.Fox, Nick C.Ghetti, BernardinoGraff-Radford, Neill R.Laske, ChristopherMartins, Ralph N.Masters, Colin L.Mayeux, Richard P.Ringman, John M.Rossor, Martin N.Salloway, Stephen P.Schofield, Peter R.Morris, John C.Bateman, Randall J.Dominantly Inherited AlzheimerNeurologicalSymptomsFamilial Alzheimerhttps://purl.org/becyt/ford/3.2https://purl.org/becyt/ford/3Background Autosomal dominant familial Alzheimer's disease (ADAD) is a rare disorder with non-amnestic neurological symptoms in some clinical presentations. We aimed to compile and compare data from symptomatic participants in the Dominantly Inherited Alzheimer Network observational study (DIAN-OBS) with those reported in the literature to estimate the prevalences of non-amnestic neurological symptoms in participants with ADAD. Methods We prospectively collected data from the DIAN-OBS database, which recruited participants from study centres in the USA, Europe, and Australia, between Feb 29, 2008, and July 1, 2014. We also did a systematic review of publications to extract individual-level clinical data for symptomatic participants with ADAD. We used data for age of onset (from first report of cognitive decline), disease course from onset to death, and the presence of 13 neurological findings that have been reported in association with ADAD. Using multivariable linear regression, we investigated the prevalences of various non-amnestic neurological symptoms and the contributions of age of onset and specific mutation type on symptoms. Findings The DIAN-OBS dataset included 107 individuals with detailed clinical data (forming the DIAN-OBS cohort). Our systematic review yielded 188 publications reporting on 1228 symptomatic individuals, with detailed neurological examination descriptions available for 753 individuals (forming the published data cohort). The most prevalent non-amnestic cognitive manifestations in participants in the DIAN-OBS cohort were those typical of mild to moderate Alzheimer's disease, including visual agnosia (55·1%, 95% CI 45·7–64·6), aphasia (57·9%, 48·6–67·3), and behavioural changes (61·7%, 51·5–70·0). Non-amnestic cognitive manifestations were less prevalent in the published data cohort (eg, visual agnosia [5·6%, 3·9–7·2], aphasia [23·0%, 20·0–26·0], and behavioural changes [31·7%, 28·4–35·1]). Prevalence of non-cognitive neurological manifestations in the DIAN-OBS cohort was low, including myoclonus and spasticity (9·3%, 95% CI 3·8–15·0), and seizures (2·8%, 0·5–5·9) and moderate for parkinsonism (11·2%, 5·3–17·1). By constrast, prevalence was higher in the published data cohort for myoclonus and spasticity (19·4%, 16·6–22·2 and 15·0%, 12·5–17·6, respectively), parkinsonism (12·5%, 10·1–15·0), and seizures (20·3%, 17·4–23·2). In an analysis of the published data cohort, ischaemic stroke was more prevalent at older ages of onset of symptoms of ADAD (odds ratio 1·09 per 1 year increase in age of onset, 95% CI 1·04–1·14, p=0·0003); and motor symptoms were more common at younger age of onset (myoclonus 0·93, 0·90–0·97, p=0·0007; seizures 0·95, 0·92–0·98, p=0·0018; corticobulbar deficits 0·91, 0·86–0·96, p=0·0012; and cerebellar ataxia 0·82, 0·74–0·91, p=0·0002). In the DIAN-OBS cohort, non-cognitive symptoms were more common at more severe stages of disease. Interpretation The non-cognitive clinical manifestations of Alzheimer's disease seem to affect a small proportion of participants with mild to moderate ADAD, and are probably influenced by disease severity, environmental, and genetic factors. When evaluating patients with potential ADAD, clinicians should note that cognitive symptoms typical of sporadic Alzheimer's disease are the most consistent finding, with some patients manifesting non-cognitive neurological symptoms. Future work is needed to determine the environmental and genetic factors that cause these neurological symptoms. Funding National Institutes of Health and German Center for Neurodegenerative Diseases.Fil: Tang, Mengxuan. Washington University. School of Medicine; Estados UnidosFil: Ryman, Davis C.. Washington University. School of Medicine; Estados UnidosFil: McDade, Eric. Washington University. School of Medicine; Estados UnidosFil: Jasielec, Mateusz S.. Washington University. School of Medicine; Estados UnidosFil: Buckles, Virginia D.. Washington University. School of Medicine; Estados UnidosFil: Cairns, Nigel J.. Washington University. School of Medicine; Estados UnidosFil: Fagan, Anne M.. Washington University. School of Medicine; Estados UnidosFil: Goate, Alison. Washington University. School of Medicine; Estados UnidosFil: Marcus, Daniel S.. Washington University. School of Medicine; Estados UnidosFil: Xiong, Chengjie. Washington University. School of Medicine; Estados UnidosFil: Allegri, Ricardo Francisco. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Chhatwal, Jasmeer P.. Brigham and Women’s Hospital; Estados UnidosFil: Danek, Adrian. Ludwig-Maximilians Universität Munich. Neurologische Klinik; AlemaniaFil: Farlow, Martin R.. Indiana University; Estados UnidosFil: Fox, Nick C.. University College London; Estados UnidosFil: Ghetti, Bernardino. Indiana University; Estados UnidosFil: Graff-Radford, Neill R.. Mayo Clinic; Estados UnidosFil: Laske, Christopher. German Center for Neurodegenerative Diseases and Hertie Institute for Clinical Brain Research; AlemaniaFil: Martins, Ralph N.. Edith Cowan University. School of Exercise, Biomedical and Health Sciences. Centre of Excellence for Alzheimer’s Disease Research and Care; AustraliaFil: Masters, Colin L.. University of Melbourne. Mental Health Research Institute; AustraliaFil: Mayeux, Richard P.. Columbia University Medical Center. Taub Institute for Research on Alzheimer’s Disease and the Aging Brain; Estados UnidosFil: Ringman, John M.. University of Southern California. Keck School of Medicine; Estados UnidosFil: Rossor, Martin N.. University College London; Estados UnidosFil: Salloway, Stephen P.. Brown University. Warren Alpert Medical School; Estados UnidosFil: Schofield, Peter R.. University of New South Wales; AustraliaFil: Morris, John C.. University of Washington; Estados UnidosFil: Bateman, Randall J.. University of Washington; Estados UnidosElsevier Science Inc2016-12info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/51545Tang, Mengxuan; Ryman, Davis C.; McDade, Eric; Jasielec, Mateusz S.; Buckles, Virginia D.; et al.; Neurological manifestations of autosomal dominant familial Alzheimer's disease: a comparison of the published literature with the Dominantly Inherited Alzheimer Network observational study (DIAN-OBS); Elsevier Science Inc; Lancet Neurology; 15; 13; 12-2016; 1317-13251474-4422CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/doi/10.1016/S1474-4422(16)30229-0info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-03T09:45:03Zoai:ri.conicet.gov.ar:11336/51545instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-03 09:45:03.627CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse |
dc.title.none.fl_str_mv |
Neurological manifestations of autosomal dominant familial Alzheimer's disease: a comparison of the published literature with the Dominantly Inherited Alzheimer Network observational study (DIAN-OBS) |
title |
Neurological manifestations of autosomal dominant familial Alzheimer's disease: a comparison of the published literature with the Dominantly Inherited Alzheimer Network observational study (DIAN-OBS) |
spellingShingle |
Neurological manifestations of autosomal dominant familial Alzheimer's disease: a comparison of the published literature with the Dominantly Inherited Alzheimer Network observational study (DIAN-OBS) Tang, Mengxuan Dominantly Inherited Alzheimer Neurological Symptoms Familial Alzheimer |
title_short |
Neurological manifestations of autosomal dominant familial Alzheimer's disease: a comparison of the published literature with the Dominantly Inherited Alzheimer Network observational study (DIAN-OBS) |
title_full |
Neurological manifestations of autosomal dominant familial Alzheimer's disease: a comparison of the published literature with the Dominantly Inherited Alzheimer Network observational study (DIAN-OBS) |
title_fullStr |
Neurological manifestations of autosomal dominant familial Alzheimer's disease: a comparison of the published literature with the Dominantly Inherited Alzheimer Network observational study (DIAN-OBS) |
title_full_unstemmed |
Neurological manifestations of autosomal dominant familial Alzheimer's disease: a comparison of the published literature with the Dominantly Inherited Alzheimer Network observational study (DIAN-OBS) |
title_sort |
Neurological manifestations of autosomal dominant familial Alzheimer's disease: a comparison of the published literature with the Dominantly Inherited Alzheimer Network observational study (DIAN-OBS) |
dc.creator.none.fl_str_mv |
Tang, Mengxuan Ryman, Davis C. McDade, Eric Jasielec, Mateusz S. Buckles, Virginia D. Cairns, Nigel J. Fagan, Anne M. Goate, Alison Marcus, Daniel S. Xiong, Chengjie Allegri, Ricardo Francisco Chhatwal, Jasmeer P. Danek, Adrian Farlow, Martin R. Fox, Nick C. Ghetti, Bernardino Graff-Radford, Neill R. Laske, Christopher Martins, Ralph N. Masters, Colin L. Mayeux, Richard P. Ringman, John M. Rossor, Martin N. Salloway, Stephen P. Schofield, Peter R. Morris, John C. Bateman, Randall J. |
author |
Tang, Mengxuan |
author_facet |
Tang, Mengxuan Ryman, Davis C. McDade, Eric Jasielec, Mateusz S. Buckles, Virginia D. Cairns, Nigel J. Fagan, Anne M. Goate, Alison Marcus, Daniel S. Xiong, Chengjie Allegri, Ricardo Francisco Chhatwal, Jasmeer P. Danek, Adrian Farlow, Martin R. Fox, Nick C. Ghetti, Bernardino Graff-Radford, Neill R. Laske, Christopher Martins, Ralph N. Masters, Colin L. Mayeux, Richard P. Ringman, John M. Rossor, Martin N. Salloway, Stephen P. Schofield, Peter R. Morris, John C. Bateman, Randall J. |
author_role |
author |
author2 |
Ryman, Davis C. McDade, Eric Jasielec, Mateusz S. Buckles, Virginia D. Cairns, Nigel J. Fagan, Anne M. Goate, Alison Marcus, Daniel S. Xiong, Chengjie Allegri, Ricardo Francisco Chhatwal, Jasmeer P. Danek, Adrian Farlow, Martin R. Fox, Nick C. Ghetti, Bernardino Graff-Radford, Neill R. Laske, Christopher Martins, Ralph N. Masters, Colin L. Mayeux, Richard P. Ringman, John M. Rossor, Martin N. Salloway, Stephen P. Schofield, Peter R. Morris, John C. Bateman, Randall J. |
author2_role |
author author author author author author author author author author author author author author author author author author author author author author author author author author |
dc.subject.none.fl_str_mv |
Dominantly Inherited Alzheimer Neurological Symptoms Familial Alzheimer |
topic |
Dominantly Inherited Alzheimer Neurological Symptoms Familial Alzheimer |
purl_subject.fl_str_mv |
https://purl.org/becyt/ford/3.2 https://purl.org/becyt/ford/3 |
dc.description.none.fl_txt_mv |
Background Autosomal dominant familial Alzheimer's disease (ADAD) is a rare disorder with non-amnestic neurological symptoms in some clinical presentations. We aimed to compile and compare data from symptomatic participants in the Dominantly Inherited Alzheimer Network observational study (DIAN-OBS) with those reported in the literature to estimate the prevalences of non-amnestic neurological symptoms in participants with ADAD. Methods We prospectively collected data from the DIAN-OBS database, which recruited participants from study centres in the USA, Europe, and Australia, between Feb 29, 2008, and July 1, 2014. We also did a systematic review of publications to extract individual-level clinical data for symptomatic participants with ADAD. We used data for age of onset (from first report of cognitive decline), disease course from onset to death, and the presence of 13 neurological findings that have been reported in association with ADAD. Using multivariable linear regression, we investigated the prevalences of various non-amnestic neurological symptoms and the contributions of age of onset and specific mutation type on symptoms. Findings The DIAN-OBS dataset included 107 individuals with detailed clinical data (forming the DIAN-OBS cohort). Our systematic review yielded 188 publications reporting on 1228 symptomatic individuals, with detailed neurological examination descriptions available for 753 individuals (forming the published data cohort). The most prevalent non-amnestic cognitive manifestations in participants in the DIAN-OBS cohort were those typical of mild to moderate Alzheimer's disease, including visual agnosia (55·1%, 95% CI 45·7–64·6), aphasia (57·9%, 48·6–67·3), and behavioural changes (61·7%, 51·5–70·0). Non-amnestic cognitive manifestations were less prevalent in the published data cohort (eg, visual agnosia [5·6%, 3·9–7·2], aphasia [23·0%, 20·0–26·0], and behavioural changes [31·7%, 28·4–35·1]). Prevalence of non-cognitive neurological manifestations in the DIAN-OBS cohort was low, including myoclonus and spasticity (9·3%, 95% CI 3·8–15·0), and seizures (2·8%, 0·5–5·9) and moderate for parkinsonism (11·2%, 5·3–17·1). By constrast, prevalence was higher in the published data cohort for myoclonus and spasticity (19·4%, 16·6–22·2 and 15·0%, 12·5–17·6, respectively), parkinsonism (12·5%, 10·1–15·0), and seizures (20·3%, 17·4–23·2). In an analysis of the published data cohort, ischaemic stroke was more prevalent at older ages of onset of symptoms of ADAD (odds ratio 1·09 per 1 year increase in age of onset, 95% CI 1·04–1·14, p=0·0003); and motor symptoms were more common at younger age of onset (myoclonus 0·93, 0·90–0·97, p=0·0007; seizures 0·95, 0·92–0·98, p=0·0018; corticobulbar deficits 0·91, 0·86–0·96, p=0·0012; and cerebellar ataxia 0·82, 0·74–0·91, p=0·0002). In the DIAN-OBS cohort, non-cognitive symptoms were more common at more severe stages of disease. Interpretation The non-cognitive clinical manifestations of Alzheimer's disease seem to affect a small proportion of participants with mild to moderate ADAD, and are probably influenced by disease severity, environmental, and genetic factors. When evaluating patients with potential ADAD, clinicians should note that cognitive symptoms typical of sporadic Alzheimer's disease are the most consistent finding, with some patients manifesting non-cognitive neurological symptoms. Future work is needed to determine the environmental and genetic factors that cause these neurological symptoms. Funding National Institutes of Health and German Center for Neurodegenerative Diseases. Fil: Tang, Mengxuan. Washington University. School of Medicine; Estados Unidos Fil: Ryman, Davis C.. Washington University. School of Medicine; Estados Unidos Fil: McDade, Eric. Washington University. School of Medicine; Estados Unidos Fil: Jasielec, Mateusz S.. Washington University. School of Medicine; Estados Unidos Fil: Buckles, Virginia D.. Washington University. School of Medicine; Estados Unidos Fil: Cairns, Nigel J.. Washington University. School of Medicine; Estados Unidos Fil: Fagan, Anne M.. Washington University. School of Medicine; Estados Unidos Fil: Goate, Alison. Washington University. School of Medicine; Estados Unidos Fil: Marcus, Daniel S.. Washington University. School of Medicine; Estados Unidos Fil: Xiong, Chengjie. Washington University. School of Medicine; Estados Unidos Fil: Allegri, Ricardo Francisco. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina Fil: Chhatwal, Jasmeer P.. Brigham and Women’s Hospital; Estados Unidos Fil: Danek, Adrian. Ludwig-Maximilians Universität Munich. Neurologische Klinik; Alemania Fil: Farlow, Martin R.. Indiana University; Estados Unidos Fil: Fox, Nick C.. University College London; Estados Unidos Fil: Ghetti, Bernardino. Indiana University; Estados Unidos Fil: Graff-Radford, Neill R.. Mayo Clinic; Estados Unidos Fil: Laske, Christopher. German Center for Neurodegenerative Diseases and Hertie Institute for Clinical Brain Research; Alemania Fil: Martins, Ralph N.. Edith Cowan University. School of Exercise, Biomedical and Health Sciences. Centre of Excellence for Alzheimer’s Disease Research and Care; Australia Fil: Masters, Colin L.. University of Melbourne. Mental Health Research Institute; Australia Fil: Mayeux, Richard P.. Columbia University Medical Center. Taub Institute for Research on Alzheimer’s Disease and the Aging Brain; Estados Unidos Fil: Ringman, John M.. University of Southern California. Keck School of Medicine; Estados Unidos Fil: Rossor, Martin N.. University College London; Estados Unidos Fil: Salloway, Stephen P.. Brown University. Warren Alpert Medical School; Estados Unidos Fil: Schofield, Peter R.. University of New South Wales; Australia Fil: Morris, John C.. University of Washington; Estados Unidos Fil: Bateman, Randall J.. University of Washington; Estados Unidos |
description |
Background Autosomal dominant familial Alzheimer's disease (ADAD) is a rare disorder with non-amnestic neurological symptoms in some clinical presentations. We aimed to compile and compare data from symptomatic participants in the Dominantly Inherited Alzheimer Network observational study (DIAN-OBS) with those reported in the literature to estimate the prevalences of non-amnestic neurological symptoms in participants with ADAD. Methods We prospectively collected data from the DIAN-OBS database, which recruited participants from study centres in the USA, Europe, and Australia, between Feb 29, 2008, and July 1, 2014. We also did a systematic review of publications to extract individual-level clinical data for symptomatic participants with ADAD. We used data for age of onset (from first report of cognitive decline), disease course from onset to death, and the presence of 13 neurological findings that have been reported in association with ADAD. Using multivariable linear regression, we investigated the prevalences of various non-amnestic neurological symptoms and the contributions of age of onset and specific mutation type on symptoms. Findings The DIAN-OBS dataset included 107 individuals with detailed clinical data (forming the DIAN-OBS cohort). Our systematic review yielded 188 publications reporting on 1228 symptomatic individuals, with detailed neurological examination descriptions available for 753 individuals (forming the published data cohort). The most prevalent non-amnestic cognitive manifestations in participants in the DIAN-OBS cohort were those typical of mild to moderate Alzheimer's disease, including visual agnosia (55·1%, 95% CI 45·7–64·6), aphasia (57·9%, 48·6–67·3), and behavioural changes (61·7%, 51·5–70·0). Non-amnestic cognitive manifestations were less prevalent in the published data cohort (eg, visual agnosia [5·6%, 3·9–7·2], aphasia [23·0%, 20·0–26·0], and behavioural changes [31·7%, 28·4–35·1]). Prevalence of non-cognitive neurological manifestations in the DIAN-OBS cohort was low, including myoclonus and spasticity (9·3%, 95% CI 3·8–15·0), and seizures (2·8%, 0·5–5·9) and moderate for parkinsonism (11·2%, 5·3–17·1). By constrast, prevalence was higher in the published data cohort for myoclonus and spasticity (19·4%, 16·6–22·2 and 15·0%, 12·5–17·6, respectively), parkinsonism (12·5%, 10·1–15·0), and seizures (20·3%, 17·4–23·2). In an analysis of the published data cohort, ischaemic stroke was more prevalent at older ages of onset of symptoms of ADAD (odds ratio 1·09 per 1 year increase in age of onset, 95% CI 1·04–1·14, p=0·0003); and motor symptoms were more common at younger age of onset (myoclonus 0·93, 0·90–0·97, p=0·0007; seizures 0·95, 0·92–0·98, p=0·0018; corticobulbar deficits 0·91, 0·86–0·96, p=0·0012; and cerebellar ataxia 0·82, 0·74–0·91, p=0·0002). In the DIAN-OBS cohort, non-cognitive symptoms were more common at more severe stages of disease. Interpretation The non-cognitive clinical manifestations of Alzheimer's disease seem to affect a small proportion of participants with mild to moderate ADAD, and are probably influenced by disease severity, environmental, and genetic factors. When evaluating patients with potential ADAD, clinicians should note that cognitive symptoms typical of sporadic Alzheimer's disease are the most consistent finding, with some patients manifesting non-cognitive neurological symptoms. Future work is needed to determine the environmental and genetic factors that cause these neurological symptoms. Funding National Institutes of Health and German Center for Neurodegenerative Diseases. |
publishDate |
2016 |
dc.date.none.fl_str_mv |
2016-12 |
dc.type.none.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion http://purl.org/coar/resource_type/c_6501 info:ar-repo/semantics/articulo |
format |
article |
status_str |
publishedVersion |
dc.identifier.none.fl_str_mv |
http://hdl.handle.net/11336/51545 Tang, Mengxuan; Ryman, Davis C.; McDade, Eric; Jasielec, Mateusz S.; Buckles, Virginia D.; et al.; Neurological manifestations of autosomal dominant familial Alzheimer's disease: a comparison of the published literature with the Dominantly Inherited Alzheimer Network observational study (DIAN-OBS); Elsevier Science Inc; Lancet Neurology; 15; 13; 12-2016; 1317-1325 1474-4422 CONICET Digital CONICET |
url |
http://hdl.handle.net/11336/51545 |
identifier_str_mv |
Tang, Mengxuan; Ryman, Davis C.; McDade, Eric; Jasielec, Mateusz S.; Buckles, Virginia D.; et al.; Neurological manifestations of autosomal dominant familial Alzheimer's disease: a comparison of the published literature with the Dominantly Inherited Alzheimer Network observational study (DIAN-OBS); Elsevier Science Inc; Lancet Neurology; 15; 13; 12-2016; 1317-1325 1474-4422 CONICET Digital CONICET |
dc.language.none.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
info:eu-repo/semantics/altIdentifier/doi/10.1016/S1474-4422(16)30229-0 |
dc.rights.none.fl_str_mv |
info:eu-repo/semantics/openAccess https://creativecommons.org/licenses/by-nc-sa/2.5/ar/ |
eu_rights_str_mv |
openAccess |
rights_invalid_str_mv |
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/ |
dc.format.none.fl_str_mv |
application/pdf application/pdf |
dc.publisher.none.fl_str_mv |
Elsevier Science Inc |
publisher.none.fl_str_mv |
Elsevier Science Inc |
dc.source.none.fl_str_mv |
reponame:CONICET Digital (CONICET) instname:Consejo Nacional de Investigaciones Científicas y Técnicas |
reponame_str |
CONICET Digital (CONICET) |
collection |
CONICET Digital (CONICET) |
instname_str |
Consejo Nacional de Investigaciones Científicas y Técnicas |
repository.name.fl_str_mv |
CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas |
repository.mail.fl_str_mv |
dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar |
_version_ |
1842268706267201536 |
score |
13.13397 |